Piperidinones, such as AMG232, are further MDM2–p53 interaction inhibitors, which are tested in a phase I clinical trial in primary and recurrent GBM (NCT03107780) (https://clinicaltrials.gov/ct2/show/NCT03107780, accessed on 30 December 2021). Here, TP53 is linked to glioblastoma.